What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 data for retatrutide, its next-generation triple-agonist obesity drug.
This was revealed during a presentation at the American Diabetes Association's 86th Scientific Sessions on June 6, with the TRANSCEND-T2D-1 trial simultaneously published in The Lancet. Retatrutide is Lilly's step-change beyond tirzepatide, the molecule behind Mounjaro and Zepbound, activating three hormone receptors (GIP, GLP-1, and glucagon) rather than two.
The ADA presentations covering TRIUMPH-1 and TRANSCEND-T2D-1 showed substantial weight loss alongside meaningful improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes. Prior Phase 3 readouts had already shown 24.2% weight loss at 72 weeks in a cardiovascular disease population and 28.7% in a knee osteoarthritis population.
After the initial pop, the shares cooled down to $1,149, up 1.6% from the previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 11 days ago when the stock gained 3.4% on the news that CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
CVS Caremark covers approximately 25 to 30 million Americans through its standard formulary template, and employers who adopt those plans will see both drugs as equally accessible options.
The Foundayo addition is separately important: it is Lilly's oral GLP-1 pill, a tablet rather than an injection, which addresses one of the primary barriers to weight-loss drug adoption, needle aversion. Getting it onto the CVS formulary eliminates the slow burn that new drugs typically face as they clear PBM access hurdles.
Eli Lilly is up 6.4% since the beginning of the year, and at $1,149 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $5,208.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
